BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

222 related articles for article (PubMed ID: 33333590)

  • 1. Nomograms for predicting overall and recurrence-free survival after trimodality therapy for esophageal adenocarcinoma.
    Merritt RE; Abdel-Rasoul M; Souza DM; Kneuertz PJ
    J Surg Oncol; 2021 Mar; 123(4):881-890. PubMed ID: 33333590
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Preoperative Nomogram to Risk Stratify Patients for the Benefit of Trimodality Therapy in Esophageal Adenocarcinoma.
    Goense L; van Rossum PSN; Xi M; Maru DM; Carter BW; Meijer GJ; Ho L; van Hillegersberg R; Hofstetter WL; Lin SH
    Ann Surg Oncol; 2018 Jun; 25(6):1598-1607. PubMed ID: 29569125
    [TBL] [Abstract][Full Text] [Related]  

  • 3. A nomogram associated with high probability of malignant nodes in the surgical specimen after trimodality therapy of patients with oesophageal cancer.
    Hayashi Y; Xiao L; Suzuki A; Blum MA; Sabloff B; Taketa T; Maru DM; Welsh J; Lin SH; Weston B; Lee JH; Bhutani MS; Hofstetter WL; Swisher SG; Ajani JA
    Eur J Cancer; 2012 Dec; 48(18):3396-404. PubMed ID: 22853875
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Survival in Patients With Esophageal Adenocarcinoma Undergoing Trimodality Therapy Is Independent of Regional Lymph Node Location.
    Sepesi B; Schmidt HE; Lada M; Correa AM; Walsh GL; Mehran RJ; Rice DC; Roth JA; Vaporciyan AA; Ajani JA; Watson TJ; Swisher SG; Low DE; Hofstetter WL
    Ann Thorac Surg; 2016 Mar; 101(3):1075-80; Discussion 1080-1. PubMed ID: 26680311
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Validation of a Nomogram Predicting Survival After Trimodality Therapy for Esophageal Cancer.
    Goense L; Merrell KW; Arnett AL; Hallemeier CL; Meijer GJ; Ruurda JP; Hofstetter WL; van Hillegersberg R; Lin SH
    Ann Thorac Surg; 2018 Nov; 106(5):1541-1547. PubMed ID: 29932887
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Neoadjuvant chemoradiation is associated with improved overall survival in older patients with esophageal cancer.
    Guttmann DM; Mitra N; Metz JM; Plastaras J; Feng W; Swisher-McClure S
    J Geriatr Oncol; 2018 Jan; 9(1):40-46. PubMed ID: 28887066
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Analysis of patients scheduled for neoadjuvant therapy followed by surgery for esophageal cancer, who never made it to esophagectomy.
    Depypere L; Thomas M; Moons J; Coosemans W; Lerut T; Prenen H; Haustermans K; Van Veer H; Nafteux P
    World J Surg Oncol; 2019 May; 17(1):89. PubMed ID: 31133018
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Nomograms for Predicting Overall and Recurrence-free Survival From Pathologic Stage IA and IB Lung Cancer After Lobectomy.
    Merritt RE; Abdel-Rasoul M; Fitzgerald M; D'Souza DM; Kneuertz PJ
    Clin Lung Cancer; 2021 Jul; 22(4):e574-e583. PubMed ID: 33234491
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Disparities in survival after trimodality therapy for esophageal adenocarcinoma.
    Eng OS; Nelson RA; Konstantinidis I; Chao J; Erhunmwunsee L; Raz DJ; Kim JY
    Dis Esophagus; 2018 Sep; 31(9):. PubMed ID: 29534155
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Nomogram to Predict Overall Survival for Thoracic Esophageal Squamous Cell Carcinoma Patients After Radical Esophagectomy.
    Deng W; Zhang W; Yang J; Ni W; Yu S; Li C; Chang X; Zhou Z; Chen D; Feng Q; Chen X; Lin Y; Zhu K; Zheng X; He J; Gao S; Xue Q; Mao Y; Cheng G; Sun K; Liu X; Fang D; Chen J; Xiao Z
    Ann Surg Oncol; 2019 Sep; 26(9):2890-2898. PubMed ID: 31183641
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Oncologic Outcomes According to Remnant Lymph Node Metastases in Pathologic T0 (ypT0) Esophageal Squamous Cell Carcinoma Following Prospective Neoadjuvant Therapy and Surgery.
    Cho HJ; Kim YH; Kim HR; Kim DK; Park SI; Kim JH; Kim SB
    Ann Surg Oncol; 2015; 22(6):1851-7. PubMed ID: 25344308
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Improved prognosis with induction chemotherapy in pathological complete responders after trimodality treatment for esophageal squamous cell carcinoma: Hypothesis generating for adjuvant treatment.
    Lu SL; Hsu FM; Tsai CL; Lee JM; Huang PM; Hsu CH; Lin CC; Chang YL; Hsieh MS; Cheng JC
    Eur J Surg Oncol; 2019 Aug; 45(8):1498-1504. PubMed ID: 30910457
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Prognostic nomogram for previously untreated patients with esophageal squamous cell carcinoma after esophagectomy followed by adjuvant chemotherapy.
    Duan J; Deng T; Ying G; Huang D; Zhang H; Zhou L; Bai M; Li H; Yang H; Qu Y; Wang X; Ba Y
    Jpn J Clin Oncol; 2016 Apr; 46(4):336-43. PubMed ID: 26819278
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Lymph node harvest in esophageal cancer after neoadjuvant chemoradiotherapy.
    Shridhar R; Hoffe SE; Almhanna K; Weber JM; Chuong MD; Karl RC; Meredith K
    Ann Surg Oncol; 2013 Sep; 20(9):3038-43. PubMed ID: 23625142
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Primary Gross Tumor Volume is an Important Prognostic Factor in Locally Advanced Esophageal Cancer Patients Treated with Trimodality Therapy.
    Boggs DH; Hanna A; Burrows W; Horiba N; Suntharalingam M
    J Gastrointest Cancer; 2015 Jun; 46(2):131-7. PubMed ID: 25759174
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development and Assessment of a Clinical Calculator for Estimating the Likelihood of Recurrence and Survival Among Patients With Locally Advanced Rectal Cancer Treated With Chemotherapy, Radiotherapy, and Surgery.
    Weiser MR; Chou JF; Keshinro A; Chapman WC; Bauer PS; Mutch MG; Parikh PJ; Cercek A; Saltz LB; Gollub MJ; Romesser PB; Crane CH; Shia J; Markowitz AJ; Garcia-Aguilar J; Gönen M;
    JAMA Netw Open; 2021 Nov; 4(11):e2133457. PubMed ID: 34748003
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A retrospective comparison of neoadjuvant chemoradiotherapy regimens for locally advanced esophageal cancer.
    Sanford NN; Catalano PJ; Enzinger PC; King BL; Bueno R; Martin NE; Hong TS; Wo JY; Mamon HJ
    Dis Esophagus; 2017 Jul; 30(7):1-8. PubMed ID: 28475728
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Predicting individual survival after potentially curative esophagectomy for adenocarcinoma of the esophagus or gastroesophageal junction.
    Lagarde SM; Reitsma JB; Ten Kate FJ; Busch OR; Obertop H; Zwinderman AH; Moons J; van Lanschot JJ; Lerut T
    Ann Surg; 2008 Dec; 248(6):1006-13. PubMed ID: 19092345
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Influence of Neoadjuvant Therapy on Poor Long-Term Outcomes of Postoperative Complications in Patients with Esophageal Squamous Cell Carcinoma: A Retrospective Cohort Study.
    Takeuchi M; Kawakubo H; Mayanagi S; Irino T; Fukuda K; Nakamura R; Wada N; Takeuchi H; Kitagawa Y
    Ann Surg Oncol; 2019 Jul; 26(7):2081-2089. PubMed ID: 30937664
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Single-institution retrospective comparison of preoperative versus definitive chemoradiotherapy for adenocarcinoma of the esophagus.
    Shridhar R; Freilich J; Hoffe SE; Almhanna K; Fulp WJ; Yue B; Karl RC; Meredith K
    Ann Surg Oncol; 2014 Nov; 21(12):3744-50. PubMed ID: 24854492
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.